ioxilan (oxilan) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Ioxilan is a nonionic X-ray contrast agent approved by the United States Food and Drug Administration for X-ray imaging contrast enhancement. Ioxilan can be administered intravenously for excretory urography and contrast-enhanced computed tomography (CT) imaging of the head and body. Ioxilan can also be given intraarterially for cerebral arteriograpy, coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography.   NCATS

Chemistry

  • SMILES: CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I
  • InChIKey: UUMLTINZBQPNGF-UHFFFAOYSA-N
  • Mol. Mass: 791.1119
  • ALogP: -0.99
  • ChEMBL Molecule:
    ioxilan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

5-(n-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-n-(2-hydroxyethyl)-n'-(2,3-dihydroxypropyl)isophthalamide | ioxilan | ioxilane | ioxilanum | ioxitol | n-(2,3-dihydroxypropyl)-n’-(2- hydroxyethyl)-5-[n-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide | oxilan | oxilan-300 | oxilan-350

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Contrast Media (approved 1995)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue